biogen unusual options activity. a whale with a lot of money to spend has taken a noticeably bearish stance on looking at options history for biogen (nasdaq:) we detected 12 strange trades. if we consider the specifics of each trade it is accurate to s

biogen (biib) gets positive fda panel vote for tofersen nda. biogen biib announced that an fda advisory committee gave a mostly favorable opinion on its new drug application (nda) seeking approval for its pipeline candidate tofersen fo

despite failed phase 3 study fda staff says biogens als drug may have clinical benefit. fda'.s peripheral and central nervous system drugs advisory committee will virtually

United States fda staff flags no new safety concerns for biogens als drug. staff reviewers of United States drug regulator on monday did not raise any new safety concerns about biogen incs experimental drug for treating a rare type of amyotrophi

fda staff says biogens als drug may have a clinical benefit on a rare form of the disease. the fda staff on monday said biogens investigational als drug tofersen may have a clinical benefit on a rare and aggressive form of the disease.

u.s. fda staff flags no new safety concerns for biogen's als drug. the u.s. food and drug administration's staff reviewers on monday did not raise any new safety concerns about biogen inc's experimental drug for treating a rare type of amyotr

u.s. fda staff flags no new safety concerns for biogen's als drug. staff reviewers of u.s. drug regulator on monday did not raise any new safety concerns about biogen inc's experimental drug for treating a rare type of amyotrophic lateral sclero

(biib) - analyzing biogens short interest. ) short percent of float has risen 8.21% since its last report. the company recently reported that it has

1 reason to buy biogen stock and 1 reason to sell. biogen (nasdaq: biib) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons. United States approval of biogens aduhelm f

relative strength alert for biogen. legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technica

fda to not hold panel meeting for biogen sages depression therapy zuranolone.

biogen should resume strong growth with zuranolone approval.

fda will review eisai and biogens alzheimers treatment leqembi with decision on full approval expected in early july. medicare has agreed to provide broader coverage once leqembi receives full fda approval.

eisai-biogen seek complete fda approval for its second alzheimers treatment. the) and

fda will review eisais and biogens alzheimers treatment leqembi with decision on full approval expected in early july. medicare has agreed to provide broader coverage once leqembi receives full fda approval.

biogen (biib) eisai seek full nod for alzheimer drug leqembi. biogen biib announced that the fda has accepted the supplemental biologics license application (sbla) filed by partner eisai. the sbla seeks traditional approval for their n

genentech sues biogen for royalties on blockbuster ms drug. roches genentech inc [roging.ul] sued biogen ma inc on tuesday in san francisco federal court claiming biogen owes additional patent royalties from worldwide sales of its blockbuster mu

peering into biogens recent short interest. ) short percent of float has fallen 8.84% since its last report. the company recently reported that it has

roches genentech sues biogen over additional patent royalties from tysabri sales.

validea daily guru fundamental report for biib - 2/17/2023. below is valideas daily guru fundamental report for biogen inc (biib). of the 22 guru strategies we follow biib rates highest using our value investor model based on the published stra

biogen (biib) beats q4 earnings & sales estimates stock up. biogen biib reported fourth-quarter 2022 adjusted earnings per share (eps) of $4.05 beating the zacks consensus estimate of $3.51. earnings rose 19% year over year driven by l

biogen inc. (biib) q4 earnings and revenues beat estimates. biogen inc. (biib) came out with quarterly earnings of $4.05 per share beating the zacks consensus estimate of $3.51 per share. this compares to earnings of $3.39 per share a

why biogen stock is falling today. ) postedsales of $2.54 billion beating the consensus of $2.44 billion down 7% y/y and 4% at constant currency (cc). multiple sclerosi

biogen sees modest 2023 revenue from alzheimers disease drug. biogen inc said on wednesday that alzheimers disease drug leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch.

biogen q4 results top estimates. (rttnews) - biotechnology company biogen inc. (biib) reported wednesday that profit for the fourth quarter surged 50 percent from last year reflecting lower expenses despite a 7 percent revenue growth. however ad

biogen inc. q4 profit increases beats estimates. (rttnews) - biogen inc. (biib) announced earnings for its fourth quarter that increased from the same period last year and beat the street estimates.

biogen earnings beat estimates on boost from muscle disorder drug. biogen inc beat wall street expectations for quarterly profit and sales on wednesday riding on strong demand for its spinal muscular atrophy drug spinraza and forecast modest rev

biogen inc. (biib) reports next week: wall street expects earnings growth. wall street expects a year-over-year increase in earnings on lower revenues when biogen inc. (biib) reports results for the quarter ended december 2022. while t

approval for anavexs blarcamesine looks inevitable after biogens leqembi approved.

biogen pt lowered to $337 at ubs.